EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients.

ABSTRACT:

Background

Despite the impressive anti-tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) patients, 30-40% of patients still show limited response. There is therefore a need to identify biomarkers that accurately predict the response to osimertinib therapy. In this study, 54 patients with targeted next-generation sequencing of circulating tumor DNA before osimertinib treatment and known T790M positivity were included. We investigated the predictive value of baseline circulating tumor DNA-derived biomarkers on osimertinib therapy.

Results

Baseline maximum somatic allele frequency (MSAF) level was not associated with objective response rate (ORR) (P = 0.886) and progression-free survival (PFS) (P = 0.370)

SUBMITTER: Zheng Q 

PROVIDER: S-EPMC7026329 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature